Catalog No.
DHC21903
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
MSK8, VNRA, Vitronectin receptor, Integrin alpha-V, Vitronectin receptor subunit alpha, CD51, ITGAV, VTNR, GPIIIa, Integrin beta-3, CD61, ITGB3, Platelet membrane glycoprotein IIIa, GP3A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06756 & P05106
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CNTO 095, CAS: 725735-28-4
Clone ID
Intetumumab
Note
For research use only. Not suitable for clinical or therapeutic use.
CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo., PMID:15095296
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding., PMID:16203788
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA., PMID:16374720
Integrins: molecular targets in cancer therapy., PMID:16507218
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models., PMID:17575234
CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells., PMID:18064530
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo., PMID:18566227
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer., PMID:20145975
Pharmacology and placental transfer of a human alphav integrin monoclonal antibody in rabbits., PMID:20151458
Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats., PMID:20841470
Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models., PMID:21123368
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma., PMID:21331745
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody., PMID:21633302
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma., PMID:21750555
Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study., PMID:22027908
Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model., PMID:22842979
The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma., PMID:23082872
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer., PMID:23104724
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer., PMID:23275294
Human monoclonal antibodies in cancer therapy: a review of recent developments., PMID:23276961
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus., PMID:23341479
Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab., PMID:24488787
Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity., PMID:24810893
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors., PMID:25527204
High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats., PMID:28739685
Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials., PMID:29797220
Integrins as A New Target for Cancer Treatment., PMID:30451118
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA, PMID: 16374720
Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models, PMID: 17575234
CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells, PMID: 18064530
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding, PMID: 16203788
CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo, PMID: 15095296
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo, PMID: 18566227
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus, PMID: 23341479
Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity, PMID: 24810893
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer, PMID: 23275294
Human monoclonal antibodies in cancer therapy: a review of recent developments, PMID: 23276961
Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials, PMID: 29797220
Integrins: molecular targets in cancer therapy, PMID: 16507218
Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study, PMID: 22027908
High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats, PMID: 28739685
Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models, PMID: 21123368
Integrins as A New Target for Cancer Treatment, PMID: 30451118
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors, PMID: 25527204
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody, PMID: 21633302
Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model, PMID: 22842979
Pharmacology and placental transfer of a human alphav integrin monoclonal antibody in rabbits, PMID: 20151458
The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma, PMID: 23082872
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer, PMID: 20145975
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer, PMID: 23104724
Metastatic signature in lung cancer is associated with sensitivity to anti-integrin α(V) monoclonal antibody intetumumab, PMID: 24488787
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma, PMID: 21331745
Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats, PMID: 20841470
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma, PMID: 21750555
For research use only. Not for human or drug use.
